Mechanical heart valve prosthesis and warfarin - Treatment quality and prognosis.

Bartosz Grzymala-Lubanski, Ashkan Labaf, Erling Englund, Peter Svensson, Anders Själander

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

Every year about 2500 patients in Sweden undergo surgery due to heart valve disease. A mechanical heart valve prosthesis causes risk of thromboembolic stroke or thrombus formation in the valve while anticoagulant treatment increases the risk of bleeding. Treatment quality with warfarin is crucial for patients with mechanical valve prostheses. It has previously been shown that poorly controlled warfarin treatment increases mortality in this patient group. TTR (Time in Therapeutic Range) on warfarin has been shown to affect the risk of complications in atrial fibrillation, but has not been studied in patients with mechanical heart valves. Our aim is to evaluate the impact of TTR on the risk of complications in this patient group.
Originalspråkengelska
Sidor (från-till)795-798
TidskriftThrombosis Research
Volym133
Nummer5
DOI
StatusPublished - 2014

Ämnesklassifikation (UKÄ)

  • Kardiologi

Fingeravtryck

Utforska forskningsämnen för ”Mechanical heart valve prosthesis and warfarin - Treatment quality and prognosis.”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här